Table 1.
Baseline characteristics of the cohort (n = 3172)
| Total | Male (n = 1713) |
Female (n = 1459) |
|
|---|---|---|---|
| Age, y [IQR] | 56 [50–63] | 56 [50–63] | 57 [51–63] |
| Sex, male, n (%) | 1713 (54.0) | N/A | N/A |
| Body mass index, kg/m2 [IQR] | 24.03 [22.11–25.96] | 24.48 [22.73–26.35] | 23.47 [21.53–25.43] |
| Hypertension, n (%) | 712 (22.4) | 420 (24.5) | 292 (20.0) |
| Diabetes, n (%) | 437 (13.8) | 390 (16.9) | 147 (10.1) |
| Hyperlipidemia, n (%) | 808 (25.5) | 403 (23.5) | 405 (27.8) |
| Ischemic heart disease, n (%) | 124 (3.9) | 73 (4.3) | 51 (3.5) |
| Current smoking, n (%) | 489 (15.4) | 445 (26.0) | 44 (3.0) |
| Current alcohol use, n (%) | 1539 (48.5) | 1148 (67.0) | 391 (26.8) |
| On antiplatelet medication, n (%) | 326 (10.3) | 210 (12.3) | 116 (8.0) |
| On antihypertensive, n (%) | 699 (22.0) | 371 (21.7) | 328 (22.5) |
| On statin, n (%) | 256 (8.1) | 143 (8.3) | 113 (7.7) |
| Fasting glucose, mg/dL [IQR] | 91 [85–101] | 93 [86–104] | 90 [84–99] |
| Total cholesterol, mg/dL [IQR] | 198 [174–223] | 194 [172–219] | 202 [178–227] |
| LDL cholesterol, mg/dL [IQR] | 124 [101–147] | 123 [101–147] | 126 [102–148] |
| HDL cholesterol, mg/dL [IQR] | 53 [45–63] | 49 [42–58] | 57 [49–67] |
| Triglycerides, mg/dL [IQR] | 100 [73–144] | 110 [78–159] | 91 [69–125] |
| TG/HDL cholesterol ratio [IQR] | 1.87 [1.23–3.02] | 2.21 [1.43–3.56] | 1.56 [1.09–2.42] |
| TC/TG ratio [IQR] | 1.95 [1.36–2.67] | 1.74 [1.23–2.44] | 2.21 [1.60–2.94] |
| White blood cells, × 103/μL [IQR] | 5.31 [4.40–6.37] | 5.61 [4.66–6.82] | 5.03 [4.15–5.98] |
| hs-CRP, mg/dL [IQR] | 0.04 [0.01–0.15] | 0.06 [0.01–0.16] | 0.03 [0.01–0.13] |
| Silent brain infarct, n (%) | 263 (8.3) | 146 (8.5) | 117 (8.0) |
| Intracranial atherosclerosis, n (%) | 95 (3.0) | 51 (3.0) | 44 (3.0) |
LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglyceride, TC total cholesterol, hs-CRP high-sensitivity C-reactive protein